US2007172877A1PendingUtilityA1

Methods for preventing cattle reproductive diseases

45
Assignee: PFIZER PROD INCPriority: Apr 21, 2003Filed: Mar 15, 2007Published: Jul 26, 2007
Est. expiryApr 21, 2023(expired)· nominal 20-yr term from priority
A61P 31/12A61P 31/22A61P 31/04C12N 2710/16734A61K 2039/552C12N 2760/18634C12N 2770/24334A61K 39/0225A61K 39/245C12N 2760/18534A61K 2039/70A61K 2039/55A61K 39/105A61P 15/04A61P 15/06A61K 39/12A61P 15/00A61K 2039/5254
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj - prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo - bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.

Claims

exact text as granted — not AI-modified
1 . A method of preventing infection in an animal that is nursing a pregnant animal, wherein the pregnant animal has been vaccinated prior to breeding with a therapeutically effective amount of a first vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1), comprising administering to the nursing animal a therapeutically effective amount of a second vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1).  
   
   
       2 . A method of preventing infection in an animal that is nursing a pregnant animal, wherein the pregnant animal has been vaccinated prior to breeding with a therapeutically effective amount of a first vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1), comprising administering to the nursing animal a therapeutically effective amount of a second vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1) and at least one antigen selected from the group consisting of: Bovine Viral Diarrhea Virus (BVDV); a modified live Parainfluenza Virus Type 3 (PIV3); a modified live Bovine Respiratory Syncytial Virus (BRSV);  Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo - prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo - bovis, Leptospira Bratislava , and  Campylobacter fetus.    
   
   
       3 . The method of  claim 1 , wherein said second vaccine composition further comprises an adjuvant.  
   
   
       4 . The method of  claim 1 , wherein said pregnant animal is a cow or a heifer.  
   
   
       5 . The method of  claim 1 , wherein said nursing animal is a calf nursing a pregnant cow.  
   
   
       6 . The method of  claim 1 , wherein said second vaccine composition is administered intramuscularly.  
   
   
       7 . The method of  claim 1 , wherein said second vaccine composition is administered subcutaneously.  
   
   
       8 . The method of  claim 1 , wherein said second vaccine composition contains from about 10 2  to about 10 10  TCID 50  units per dose of each virus.  
   
   
       9 . The method of  claim 1 , wherein the amount of said second vaccine composition administered is from about 0.1 to about 5.0 ml per dose.  
   
   
       10 . The method of  claim 1 , wherein the amount of said second vaccine composition administered is about 5 ml per dose.  
   
   
       11 . The method of  claim 1 , wherein the amount of said second vaccine composition administered is about 2 ml per dose.  
   
   
       12 . The method of  claim 2 , wherein said second vaccine further comprises an adjuvant.  
   
   
       13 . The method of  claim 2 , wherein said pregnant animal is a cow or a heifer.  
   
   
       14 . The method of  claim 2 , wherein said nursing animal is a calf nursing a pregnant cow.  
   
   
       15 . The method of  claim 2 , wherein said second vaccine composition is administered intramuscularly.  
   
   
       16 . The method of  claim 2 , wherein said second vaccine composition is administered subcutaneously.  
   
   
       17 . The method of  claim 2 , wherein said second vaccine composition contains from about 10 2  to about 10 10  TCID 50  units per dose of each virus.  
   
   
       18 . The method of  claim 2 , wherein the amount of said second vaccine composition administered is from about 0.1 to about 5.0 ml per dose.  
   
   
       19 . The method of  claim 2 , wherein the amount of said second vaccine composition administered is about 5 ml per dose.  
   
   
       20 . The method of  claim 2 , wherein the amount of said second vaccine composition administered is about 2 ml per dose.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.